Nurix Therapeutics, Inc. NRIX Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards?
- Nurix Therapeutics, Inc. (NRIX) reported share-based payment - unrecognized cost of nonvested awards of $89.8M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Nurix Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards increased by 7.5% year-over-year, from $83.5M to $89.8M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.